DiaSorin S.p.A
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under L… Read more
Market Cap & Net Worth: DiaSorin S.p.A (DSRLF)
DiaSorin S.p.A (PINK:DSRLF) has a market capitalization of $5.78 Billion ($5.78 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #4242 globally and #2674 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DiaSorin S.p.A's stock price $109.60 by its total outstanding shares 52756852 (52.76 Million).
DiaSorin S.p.A Market Cap History: 2015 to 2025
DiaSorin S.p.A's market capitalization history from 2015 to 2025. Data shows growth from $2.55 Billion to $5.78 Billion (10.82% CAGR).
DiaSorin S.p.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DiaSorin S.p.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.80x
DiaSorin S.p.A's market cap is 4.80 times its annual revenue
0.68x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
30.26x
DiaSorin S.p.A's market cap is 30.26 times its annual earnings
359.02x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.55 Billion | $499.18 Million | $100.42 Million | 5.11x | 25.41x |
| 2016 | $2.70 Billion | $569.31 Million | $112.38 Million | 4.75x | 24.06x |
| 2017 | $4.47 Billion | $637.49 Million | $139.88 Million | 7.01x | 31.95x |
| 2018 | $4.08 Billion | $669.20 Million | $158.13 Million | 6.10x | 25.83x |
| 2019 | $6.74 Billion | $706.32 Million | $175.74 Million | 9.54x | 38.35x |
| 2020 | $10.61 Billion | $881.30 Million | $247.87 Million | 12.04x | 42.81x |
| 2021 | $10.51 Billion | $1.24 Billion | $310.97 Million | 8.49x | 33.81x |
| 2022 | $7.69 Billion | $1.36 Billion | $240.91 Million | 5.65x | 31.92x |
| 2023 | $5.26 Billion | $1.15 Billion | $159.85 Million | 4.58x | 32.93x |
| 2024 | $5.69 Billion | $1.19 Billion | $188.10 Million | 4.80x | 30.26x |
Competitor Companies of DSRLF by Market Capitalization
Companies near DiaSorin S.p.A in the global market cap rankings as of March 18, 2026.
Key companies related to DiaSorin S.p.A by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
DiaSorin S.p.A Historical Marketcap From 2015 to 2025
Between 2015 and today, DiaSorin S.p.A's market cap moved from $2.55 Billion to $ 5.78 Billion, with a yearly change of 10.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.78 Billion | +1.60% |
| 2024 | $5.69 Billion | +8.11% |
| 2023 | $5.26 Billion | -31.54% |
| 2022 | $7.69 Billion | -26.86% |
| 2021 | $10.51 Billion | -0.93% |
| 2020 | $10.61 Billion | +57.46% |
| 2019 | $6.74 Billion | +65.03% |
| 2018 | $4.08 Billion | -8.64% |
| 2017 | $4.47 Billion | +65.30% |
| 2016 | $2.70 Billion | +5.99% |
| 2015 | $2.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of DiaSorin S.p.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.78 Billion USD |
| MoneyControl | $5.78 Billion USD |
| MarketWatch | $5.78 Billion USD |
| marketcap.company | $5.78 Billion USD |
| Reuters | $5.78 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.